Paul Capital Partners

Paul Capital Partners was a prominent private equity firm that specialized in secondary private equity and healthcare royalty finance. Founded in 1991, the firm was a pioneer in the healthcare royalty space, providing non-dilutive capital to pharmaceutical companies, biotechnology firms, and academic institutions in exchange for future royalty streams from approved products. The firm's healthcare division focused on late-stage and commercial-stage assets, helping organizations monetize their intellectual property to fund further research or operations. At its peak, Paul Capital managed several billion dollars across multiple funds and was instrumental in establishing royalties as a distinct asset class in the life sciences sector. The firm ceased raising new funds in the early 2010s and has since transitioned into a wind-down phase of its remaining portfolio.